CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Grant or award President and CEO acquired 180,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 65,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 60,000 shares (grant or award)
- 4 Planned sale Chief Scientific Officer sold 4,000 shares at $12.51 ($50,040)
- 4 Open-market sale President and CEO sold 8,400 shares at $11.87 ($99,708)
- 4 Open-market sale Chief Scientific Officer sold 4,693 shares at $11.41 ($53,547)
- 4 Open-market sale Chief Medical Officer sold 4,632 shares at $11.41 ($52,851)
- 4 Open-market sale Chief Legal Officer sold 3,482 shares at $11.41 ($39,730)
- 4 Open-market sale Chief Scientific Officer sold 3,489 shares at $12.52 ($43,682)
- 4 Planned sale Chief Scientific Officer sold 8,000 shares at $15.64 ($125,120)
- 4 Planned sale Chief Scientific Officer sold 8,000 shares at $18.09 ($144,720)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Scientific Officer sold 8,000 shares at $16.33 ($130,640)
- 4 Grant or award Chief Scientific Officer acquired 2,360 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Director acquired 18,450 shares (option exercise)
Page 4 of 13 · 253 filings